That's quite a specific and complex diagnosis — CD5-positive germinal center DLBCL with the IGH-BCL2 translocation at stage 3 is a less common subtype, and it's completely understandable to want to connect with others who've been through something similar.
While specific member experiences with this exact subtype aren't Show Full Answer
That's quite a specific and complex diagnosis — CD5-positive germinal center DLBCL with the IGH-BCL2 translocation at stage 3 is a less common subtype, and it's completely understandable to want to connect with others who've been through something similar.
While specific member experiences with this exact subtype aren't available here, what is known is that stage 3 DLBCL is considered advanced-stage disease. The standard first-line treatment is typically R-CHOP, which consists of:
- Rituximab (Rituxan)
- Cyclophosphamide
- Doxorubicin
- Vincristine
- Prednisone
Six cycles of R-CHOP are the usual recommendation for advanced-stage DLBCL. Another FDA-approved first-line option for advanced DLBCL is Pola-R-CHP, which replaces vincristine with polatuzumab vedotin and has shown strong results.
Given the BCL2 translocation, an oncologist may also discuss targeted therapies or clinical trials, as researchers are actively exploring treatments aimed at specific genetic changes in DLBCL. It's worth asking your oncologist directly about options tailored to your molecular profile.
The MyLymphomaTeam community is a great place to post this question — members with similar subtypes may have firsthand experience to share.
May 12
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
